Kewaunee Scientific recorded third quarter sales of $69.4 million, up 3.3% year-over-year, with pre-tax earnings rising 25.8% to $1.6 million. Net earnings declined to $0.7 million, or $0.23 per diluted share, compared with $1.35 million, or $0.45 per share, in the prior year.

Domestic segment sales fell 2.0% to $51.0 million, driving net earnings down to $2.29 million and segment EBITDA to $4.10 million on lower laboratory construction volumes. International revenue surged 21.4% to $18.4 million, with net earnings of $1.26 million and EBITDA of $1.96 million, bolstered by billings in the Indian market. Corporate segment pre-tax loss was $3.06 million, with EBITDA of negative $2.26 million, reflecting strategic investments in people and technology.

Cash on hand was $10.3 million and working capital stood at $54.8 million. Short-term debt increased to $7.35 million while long-term debt declined to $42.3 million, improving the debt-to-equity ratio, net of lease obligations, to 0.31:1 from 0.57:1 a year earlier.

Integration of the Nu Aire acquisition expanded the laboratory product portfolio with end-user containment lines that offset seasonal construction softness. The company is investing in its corporate platform, including financial consolidation systems and enhanced SEC reporting readiness, to support accelerated inorganic growth.